The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Norio Yasui-Furukori

Department of Neuropsychiatry

Hirosaki University Graduate School of Medicine

Hirosaki

Japan

[email]@cc.hirosaki-u.ac.jp

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Neuropsychiatry, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 2002 - 2012

References

  1. No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Yasui-Furukori, N., Fujii, A., Sugawara, N., Tsuchimine, S., Saito, M., Hashimoto, K., Kaneko, S. Hum. Psychopharmacol (2012) [Pubmed]
  2. Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Yasui-Furukori, N., Nakagami, T., Kaneda, A., Inoue, Y., Suzuki, A., Otani, K., Kaneko, S. Hum. Psychopharmacol (2011) [Pubmed]
  3. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Yasui-Furukori, N., Saito, M., Nakagami, T., Sugawara, N., Sato, Y., Tsuchimine, S., Furukori, H., Kaneko, S. Prog. Neuropsychopharmacol. Biol. Psychiatry (2010) [Pubmed]
  4. Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients. Yasui-Furukori, N., Furukori, H., Sugawara, N., Tsuchimine, S., Fujii, A., Inoue, Y., Kaneko, S. Hum. Psychopharmacol (2010) [Pubmed]
  5. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. Yasui-Furukori, N., Furukori, H., Sugawara, N., Fujii, A., Kaneko, S. J. Clin. Psychopharmacol (2010) [Pubmed]
  6. No association between polymorphism in tyrosine hydroxylase and personality traits in healthy Japanese subjects. Tsuchimine, S., Yasui-Furukori, N., Kaneda, A., Saito, M., Nakagami, T., Sugawara, N., Kaneko, S. Psychiatry Clin. Neurosci. (2010) [Pubmed]
  7. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. Yasui-Furukori, N., Saito, M., Nakagami, T., Furukori, H., Suzuki, A., Kondo, T., Kaneko, S. J. Psychopharmacol. (Oxford) (2010) [Pubmed]
  8. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. Yasui-Furukori, N., Sato, Y., Furukori, H., Saito, M., Nakagami, T., Kaneko, S. J. Clin. Psychiatry (2009) [Pubmed]
  9. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Yasui-Furukori, N., Saito, M., Tsuchimine, S., Nakagami, T., Sato, Y., Sugawara, N., Kaneko, S. Prog. Neuropsychopharmacol. Biol. Psychiatry (2008) [Pubmed]
  10. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Yasui-Furukori, N., Tsuchimine, S., Saito, M., Nakagami, T., Sato, Y., Kaneko, S. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) [Pubmed]
  11. Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese. Yasui-Furukori, N., Kaneda, A., Iwashima, K., Saito, M., Nakagami, T., Tsuchimine, S., Kaneko, S. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2007) [Pubmed]
  12. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Yasui-Furukori, N., Saito, M., Niioka, T., Inoue, Y., Sato, Y., Kaneko, S. Ther. Drug. Monit (2007) [Pubmed]
  13. Different serum concentrations of steady-state valproic acid in two sustained-release formulations. Yasui-Furukori, N., Saito, M., Nakagami, T., Niioka, T., Sato, Y., Fujii, A., Kaneko, S. Psychiatry Clin. Neurosci. (2007) [Pubmed]
  14. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Yasui-Furukori, N., Saito, M., Inoue, Y., Niioka, T., Sato, Y., Tsuchimine, S., Kaneko, S. Eur. J. Clin. Pharmacol. (2007) [Pubmed]
  15. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Yasui-Furukori, N., Saito, M., Nakagami, T., Kaneda, A., Tateishi, T., Kaneko, S. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) [Pubmed]
  16. Digitalis intoxication induced by paroxetine co-administration. Yasui-Furukori, N., Kaneko, S. Lancet (2006) [Pubmed]
  17. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Yasui-Furukori, N., Uno, T., Sugawara, K., Tateishi, T. Clin. Pharmacol. Ther. (2005) [Pubmed]
  18. Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. Yasui-Furukori, N., Inoue, Y., Kaneko, S., Otani, K. J. Pharm. Biomed. Anal (2005) [Pubmed]
  19. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Yasui-Furukori, N., Kondo, T., Mihara, K., Inoue, Y., Kaneko, S. Psychopharmacology (Berl.) (2004) [Pubmed]
  20. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Yasui-Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., Inoue, Y., Kaneko, S., Tateishi, T. Br. J. Clin. Pharmacol (2004) [Pubmed]
  21. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Yasui-Furukori, N., Mihara, K., Takahata, T., Suzuki, A., Nakagami, T., De Vries, R., Tateishi, T., Kondo, T., Kaneko, S. Br. J. Clin. Pharmacol (2004) [Pubmed]
  22. Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography. Yasui-Furukori, N., Inoue, Y., Chiba, M., Tateishi, T. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2004) [Pubmed]
  23. Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol. Yasui-Furukori, N., Saito, M., Furukori, H., Inoue, Y., Someya, T., Kaneko, S., Tateishi, T. Ther. Drug. Monit (2004) [Pubmed]
  24. Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Yasui-Furukori, N., Furukori, H., Nakagami, T., Saito, M., Inoue, Y., Kaneko, S., Tateishi, T. Ther. Drug. Monit (2004) [Pubmed]
  25. Sensitive determination of midazolam and 1'-hydroxymidazolam in plasma by liquid-liquid extraction and column-switching liquid chromatography with ultraviolet absorbance detection and its application for measuring CYP3A activity. Yasui-Furukori, N., Inoue, Y., Tateishi, T. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2004) [Pubmed]
  26. Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. Yasui-Furukori, N., Takahata, T., Kondo, T., Mihara, K., Kaneko, S., Tateishi, T. Br. J. Clin. Pharmacol (2003) [Pubmed]
  27. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. Yasui-Furukori, N., Kondo, T., Mihara, K., Suzuki, A., Inoue, Y., Kaneko, S. J. Clin. Psychopharmacol (2003) [Pubmed]
  28. Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay. Yasui-Furukori, N., Furukori, H., Saito, M., Inoue, Y., Kaneko, S., Tateishi, T. Ther. Drug. Monit (2003) [Pubmed]
  29. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. Yasui-Furukori, N., Furuya, R., Takahata, T., Tateishi, T. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2002) [Pubmed]
  30. The characteristics of side-effects of bromperidol in schizophrenic patients. Yasui-Furukori, N., Kondo, T., Ishida, M., Tanaka, O., Mihara, K., Kaneko, S., Otani, K. Psychiatry Clin. Neurosci. (2002) [Pubmed]
  31. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Yasui-Furukori, N., Kondo, T., Suzuki, A., Mihara, K., Kaneko, S. Psychopharmacology (Berl.) (2002) [Pubmed]
 
WikiGenes - Universities